Arcus Biosciences (RCUS) Tops Q3 EPS by 2c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.00), $0.02 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $48 million versus the consensus estimate of $38.95 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Goldman Sachs Upgrades China Resources Microelectronics Ltd (688396:CH) to Neutral
• Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
• JPMorgan Upgrades YDUQS Participacoes SA (YDUQ3:BZ) to Overweight